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Abstract 
 
Background: Improved biomarkers are needed to aid in clinical decision making and as 
surrogate endpoints in clinical trials in multiple sclerosis (MS). 
 
Objective: To assess whether combinations of neurodegenerative and neuroinflammatory 
markers in cerebrospinal fluid (CSF) at diagnostic CSF sampling could predict disease 
activity during two years of follow-up in patients with clinically isolated syndrome (CIS) and 
MS.  
 
Methods: Using multiplex bead array and enzyme-linked immunosorbent assay, CXCL1, 
CXCL8, CXCL10, CXCL13, CCL20, CCL22, neurofilament light chain (NFL), 
neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1, matrix 
metalloproteinase-9 and osteopontin were analysed in CSF in 44 patients with CIS or MS and 
23 healthy controls.  
 
Results: In a logistic regression analysis model, NFL in CSF at baseline correctly classified 
93% of patients that showed evidence of disease activity (relapses, magnetic resonance 
imaging activity or disability worsening) during two years of follow-up and 62% of patients 
that did not, with an overall percentage of 83% correctly classified. Combining NFL with 
CCL22 and osteopontin improved results to overall 91% correctly classified. 
 
Conclusions: This study demonstrates the prognostic value of NFL in baseline-CSF in CIS 
and MS and indicates an added value of combining NFL with inflammatory markers.  
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1. Introduction 
 
Multiple sclerosis (MS) is a chronic disease characterized by inflammation and degeneration 
of the central nervous system (CNS). The prognosis in MS is highly variable and magnetic 
resonance imaging (MRI), although being a very important diagnostic and follow-up tool, is 
not an optimal prognostic tool since conventional MRI data, like T2 lesion load, correlate 
poorly to the clinical disease manifestations and disease progression1. Hence, there is a need 
for non-MRI biomarkers in MS to aid individualized pharmacological treatment early in the 
disease course. The ample research in MS biomarkers has recently been reviewed2-4. 
Neurofilament light chain (NFL) in CSF has been reported to correlate to long term (8 – 20 
years) prognosis5 and treating MS with fingolimod and natalizumab has been shown to 
decrease NFL levels6, 7. Whether it is appropriate or not to measure NFL in CSF when 
monitoring response to treatment, to guide clinical decisions on therapy, is currently debated8, 
9. There are complex relationships and overlaps between neuroinflammation and 
neurodegeneration in MS. Inflammatory biomarkers and markers of axonal damage in CSF 
have been shown to correlate, in different combinations in different types of MS10. However, 
results are inconsistent and there is no biomarker that is entirely specific for MS3.  
 
In this study, we evaluated a broad panel of neurodegenerative and inflammatory markers. 
NFL, neurofilament heavy chain (NFH) and glial fibrillary acidic protein (GFAP) were 
included as established markers of axonal degeneration11 and astrogliosis3, respectively. 
Chitinase-3-like 1 protein (CHI3L1) is as a marker of activated astrocytes and microglia3 and 
matrix metallopeptidase 9 (MMP-9) is a matrix degrading enzyme that both have been 
suggested as surrogate markers of disease activity in multiple sclerosis12, 13. Osteopontin 
(OPN) is an early activation marker on T cells14 that has been reported to be increased in 
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MS15. Chemokines are attractive markers because they recruit specific inflammatory cells and 
reflect ongoing type of inflammation. Also, chemokines are generally present at higher 
concentrations than cytokines and thereby easier to reliably measure in plasma and CSF. In 
MS, CXCL13 (a B cell chemoattractant) has been reported to be elevated in CSF16 and 
associated with disease exacerbations and unfavorable prognosis17. Chemokines recruit 
different settings of Th subsets and they therefore represent and can be used as markers of 
Th1 (CXCL1, CXCL10), Th2 (CCL22) and Th17 (CXCL8, CCL20) immunity18.  
 
There is no universally accepted definition of freedom of disease activity in MS. “No 
evidence of disease activity” (NEDA) is increasingly used as a comprehensive measure of 
treatment response in MS and the combination of no relapses, no brain MRI activity (new or 
enlarging T2 lesions or Gadolinium-enhancing lesions) and no disability worsening is often 
called NEDA-3. Expanding the NEDA concept to NEDA-4, where brain volume loss is 
added, or NEDA-5, where a biomarker in CSF or serum is also added, is currently 
discussed19. 
 
This study aimed to assess whether concentrations of neurodegenerative and 
neuroinflammatory markers in CSF and plasma at baseline were able to predict disease 
activity during two years of follow-up in a longitudinal cohort of patients with CIS and MS, 
and to identify the best prognostic markers in our material. In this study we report that NFL in 
CSF at baseline classified 83% of patients correctly with regard to NEDA-3 or not NEDA-3 
for two years of follow-up. Combining NFL with CCL22 and OPN improved results to 91% 
correctly classified patients.  
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Material and methods 
 
Patients and controls 
 
44 patients with CIS or MS were consecutively enrolled in a prospective longitudinal cohort 
study of CIS and newly diagnosed MS at the Department of Neurology at the University 
Hospital in Linköping, Sweden. All patients fulfilled the revised McDonald criteria from 
201020 for CIS or MS. Patients underwent clinical neurological examination including 
expanded disability status scale (EDSS), peripheral blood and CSF sampling and MRI at 
baseline and at one and two years of follow-up. Patients received immunomodulatory 
treatment according to Swedish clinical practice. Patient characteristics are presented in Table 
1 and Table 2.  
 
For peripheral blood and CSF, 23 age- and sex-matched healthy controls (HC) were recruited 
from healthy blood donors (Table 1). Healthy controls were free from past and current 
neurological and autoimmune disease and their clinical neurological examinations were 
normal as were routine findings in CSF (Table 1). No medication, except oral contraceptive 
pills, was allowed in healthy controls.  
 
Table 1. Patient and healthy control characteristics at baseline. 
 
Clinical and laboratory data Patients n=44 
Healthy controls 
n=23 p-value 
Women/men (%women) 35/9 (80%) 18/5 (78%) 0.9 
Age median, 25:th-75:th percentile 31 (25-42) 32 (26-46) 0.4 
Diagnosis (CIS/RRMS/PPMS) 19/22/3 NA  
Relapse within last 3 months  25 NA  
Relapse within last 2 months  23 NA  
Relapse within last 1 months  16 NA  
Mean disease duration (months) 13 NA  
Median disease duration (months) 4.8 NA  
Disease duration (number of subjects)   NA  
0-1 months 10   
1.25-2 months 7   
2.25-3 months 3   
3.25-6 months 6   
6.5-12 months 7   
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13-24 months 5   
25-36 months 2   
37-48 months 1   
49-60 months 1   
61-72 months 1   
120 months 1   
Median EDSS 2.0 NA  
EDSS (number of subjects)     
0 6 23  
1.0 12   
1.5 2   
2.0 14   
2.5 4   
3.0 1   
3.5 2   
4.0 2   
4.5 1   
Treatment (number of subjects on DMT) 0 NA  
CSF mononuclear cell count* 4.5 (1.9-8.9) 2.1 (0.9-2.6) 0.001 
Albumin ratio* 4.8 (3.4-5.8) 4.9 (3.6-5.5) 0.7 
IgG index* 0.7 (0.5-1.2) 0.5 (0.5-0.5) <0.001 
IgG synthesis index* 1.3 (1.0-2.2) 0.9 (0.9-1.0) <0.001 
Oligoclonal CSF IgG bands (pos/neg)  35/9 0/23  
P-values from Chi-square test for sex distribution and Mann-Whitney U test for independent samples for age 
and CSF data. 
*Median and within brackets interquartile range.  
NA, not applicable 
DMT, disease-modifying treatment 
 
Table 2. Patient diagnoses, relapse status and treatment status at baseline and at one and two years of follow-up.  
 
Clinical and laboratory data Baseline 1 year 2 years 
Number of subjects 44 44 43 
Diagnosis (CIS/RRMS/PPMS) 19/22/3 12/29/3 9/31/3 
Relapse within last 2 months (yes/no) 23/21 4/40 2/41 
Treatment (number of subjects)    
No DMT 44 20 21 
Interferon-β 1b 0 18 12 
Interferon-β 1a 0 1 1 
Fingolimod 0 1 2 
Natalizumab 0 4 7 
 
Ethics Statement 
 
The study was approved by The Regional Ethics Committee in Linköping and written 
informed consent was obtained from all participants. 
 
Cerebrospinal fluid and plasma analyses 
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All CSF sampling was carried out by the same neurologist (IH) and CSF was always collected 
8 – 12 a.m. Plasma samples were collected directly after CSF collection. One aliquot of the 
CSF sample was used for cell counting, CSF/serum albumin ratio, IgG index, IgG synthesis 
index and isoelectric focusing for detection of oligoclonal IgG bands, all according to clinical 
routines performed at the Department of Clinical Chemistry. Within one hour, the remaining 
CSF was centrifuged (300 x g for 10 min.) and the supernatant was aliquoted and immediately 
frozen and stored at -70°C until use.  
Plasma and CSF samples were analyzed for cytokine and chemokine concentrations with a 
multiplex bead assay (Milliplex® MAP kits (EMD Millipore Corporation, St. Charles, 
Missouri, USA)) according to the manufacturer’s instructions, except that an additional lower 
standard point was added to the standard curve. The measurements were performed using 
Luminex®200™ (Invitrogen, Merelbeke, Belgium). For data acquisition the software 
program xPONENT 3.1™ (Luminex Corporation, Austin, Texas, USA) was used, and for 
data analysis MasterPlex® Reader Fit was used. The detection limits were 16 pg/ml for 
CXCL1, CXCL10 and CCL22, 3.2 pg/ml for CXCL8, 3.9 pg/ml for CXCL13 and 9.8 pg/ml 
for CCL20. Values below the detection limit were assigned half the value of the detection 
limit.  
CSF NFL concentrations were measured using the NF-light assay according to instructions 
from the manufacturer (UmanDiagnostics, Umeå, Sweden). CSF NFH concentrations were 
measured using the Phosphorylated NEFH (Human) ELISA Kit according to instructions 
from the manufacturer (Abnova, Taipei City, Taiwan). CSF MMP-9 concentrations were 
measured using the Human MMP-9 Base Kit according to instructions from the manufacturer 
(Meso Scale Discovery, Rockville, Maryland). CSF GFAP concentrations were measured 
using an in house ELISA as previously described21. CSF CHI3L1 and OPN concentrations 
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were measured using commercially available ELISAs (R&D Systems, Inc. Minneapolis, 
MN). The lower limits of quantification for the NFH and MMP-9 assays were 31.2 and 122 
pg/mL, respectively. For the other analytes, all samples had concentrations within the 
quantifiable range of the assay. All measurements were performed in one round of 
experiments using one batch of reagents by board-certified laboratory technicians who were 
blinded to clinical information. Intra-assay coefficients of variation were below 15%.  
Magnetic resonance imaging 
All MR examinations were performed on a 1.5 T Achieva MRI system (Philips Healthcare, 
Best, The Netherlands). The examination protocol consisted of a: Axial T2w FLAIR Turbo 
spin echo (TSE), field of view (FOV) 230*183*129 mm, acquired resolution (acq.res.) 
0.9*1.14*3 mm, (reconstructed resolution (rec.res.) 0.9*0.9*3 mm, repetition time (TR) 6 s, 
inversion time (TI) 2 s and echo time (TE) 120 ms. Sagittal T2W FLAIR, TSE, FOV 
230*230*100 mm, acq.res. 0.9*1.12*4, rec.res. 0.9*0.9*4, TR 6 s, TE 120 ms, TI 2 s. Axial 
T2W, TSE, FOV 230*184*129 mm, SENSE 2, acq.res. 0.6*0.77*3 rec.res. 0.45*0.45*3, TR 
4.4 s TE 100 ms. Axial T1W, spin echo (SE), FOV 230*183*129 mm, SENSE 1.3, acq.res. 
0.9*1.12*3 mm, rec.res 0.9*0.9*3 mm, TR 0.6 s and TE 15 ms. The Axial T1w was 
performed both before and after contrast infection of 0.1 mmol/kg gadolinium (Bayer Pharma 
AG, Berlin, Germany). 
Statistics 
 
Statistical analyses were performed using SPSS for Windows, version 23. Since the measured 
parameters did not show a Gaussian distribution, non-parametric tests were primarily used. 
The Mann-Whitney U-test was used to compare two groups and p-values <0.01 were 
considered to be significant. To compare multiple study groups, the Kruskal–Wallis test was 
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first performed, and when p <0.05, the Mann–Whitney U-test was used as a post-hoc test and 
p-values <0.01 were considered to be significant. All p-values were based on two-tailed 
statistical tests. The stringent use of p-values was motivated by multiple testing. Non-
parametric bivariate correlation analysis (Spearman) was used when investigating possible 
association between NFL and variables where normal distribution could not be assumed, 
except between NFL and a dichotomous variable, in which case point-biserial correlation 
analysis was used. Logistic regression analysis was used when investigating if NFL alone or 
in combination with other variables could predict disease activity during follow-up. Receiver 
operating characteristic (ROC) curves were derived from logistic regression to investigate the 
discriminatory power of NFL between patients and healthy controls and between patients with 
and without disease activity during follow-up. 
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Results 
 
Neurodegenerative and neuroinflammatory markers in patients at baseline and in 
healthy controls 
 
At baseline, when all 44 patients were untreated, CSF levels of NFL, NFH, CHI3L1, MMP-9, 
CXCL1, CXCL8, CXCL10, CXCL13 and CCL22 were significantly higher in patients than in 
HC, whereas GFAP and OPN did not differ between patients and HC (Table 3). CCL20 levels 
in CSF were below the detection level in both patients and HC and CXCL13 in CSF was 
below the detection level in HC. Patients and HC did not differ in plasma levels in any of the 
cytokines or chemokines.  
 
Table 3. Neurodegenerative and neuroinflammatory markers in patients at baseline and in healthy controls. 
 
 Patients n=44  
Healthy controls 
n=23  p 
 Concentration pg/ml 
Measurable 
level  
n (%) 
Concentration pg/ml 
Measurable 
level  
n (%) 
 
CSF NFL  838 (322-2035) 44 (100) 222 (154-291) 23 (100) <0.001 
CSF NFH 36 (16-67) 28 (64) 16 (16-16) 5 (22) ≤0.01 
CSF GFAP  471 (353-646) 44 (100) 442 (344-500) 23 (100) 0.20 
CSF CHI3L1 100663 (75972-181132) 44 (100) 73549 (61412-101061) 23 (100) ≤0.01 
CSF MMP-9  226 (61-611) 31 (70) 61 (61-61) 1 (4) <0.001 
CSF OPN 83 (56-122) 44 (100) 67 (44-99) 19 (83) 0.24 
CSF CXCL1  16 (8-24) 25 (57) 8 (8-8) 4 (17) ≤0.01 
CSF CXCL8  25 (22-29) 44 (100) 17 (14-21) 23 (100) <0.001 
CSF CXCL10  1053 (806-1996) 44 (100) 540 (450-818) 23 (100) <0.001 
CSF CXCL13  5 (2-18) 26 (59) UD 0 (0) <0.001 
CSF CCL20 UD 0 (0) UD 0 (0)  
CSF CCL22  21 (8-53) 30 (68) 8 (8-8) 1 (4) <0.001 
P CXCL1  413 (212-556) 44 (100) 287 (145-548) 23 (100) 0.30 
P CXCL8  8 (2-31) 32 (73) 6 (2-19) 16 (70) 0.54 
P CXCL10  327 (237-556) 44 (100) 395 (236-553) 23 (100) 0.64 
P CXCL13  29 (21-41) 44 (100) 27 (20-32) 13 (56) 0.33 
P CCL20  5 (5-5) 9 (20) 5 (5-11) 6 (26) 0.50 
P CCL22  980 (766-1248) 44 (100) 1075 (736-1166) 23 (100) 0.82 
Concentrations are presented as median and within brackets interquartile range.  
UD = Under detection limit. 
P-values from Mann-Whitney U test for independent samples, patients compared to healthy controls, significant 
differences are in bold. 
 
The patients were also stratified by diagnosis (CIS and RRMS) and relapse status, see 
supplementary text and Tables S1 and S2. Of note is that NFL in CSF at baseline was not 
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significantly higher in patients with relapse than in relapse-free patients, regardless if time 
from onset of relapse was within two months before CSF collection (Table S2) or whether it 
was defined as within one or three months (data not shown). NFL at baseline did not correlate 
to patient age, EDSS or MSSS, but there was a correlation to mononuclear cells in CSF at 
baseline (Spearman´s rho 0.41). 
 
There were moderate to strong positive correlations between several of the neurodegenerative 
and neuroinflammatory markers in CSF at baseline, see supplementary Table S3. 
 
To evaluate how well NFL at baseline discriminated between patients and HC, we performed 
logistic regression analysis and constructed an ROC curve (Figure 1), from which sensitivity 
and specificity were calculated. An NFL value ≥453 pg/ml captured 73% of patients and had 
a specificity of 83%. An NFL value ≥847 pg/ml captured only 50% of patients but had a 
specificity of 100% in our cohort. With logistic regression analysis based on NFL, 73% of 
patients and 83% of HC could be correctly classified, with an overall correctly classified 
proportion of 76%.  
 
 Figure 1. Receiver operating characteristics (ROC) curve for NFL in CSF regarding 
separation of CIS and MS patients (n = 44) and HC (n = 23). Area under curve (AUC), 
representing the proportion of correctly classified patients versus controls, is 0.85, p<0.001.  
 
Neurodegenerative and neuroinflammatory markers in patients at baseline in relation to 
disease activity during follow-up 
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CSF levels of NFL, NFH, OPN, CXCL1, CXCL10, CXCL13 and CCL22 at baseline were 
significantly lower in patients with NEDA than EDA (evidence of disease activity) at one 
year (data not shown) and two years of follow-up (Supplementary Table S4) (Figure 2). 
Baseline CSF levels of CHI3L1, MMP-9 and CXCL8 were significantly lower in patients 
with NEDA than EDA at one year of follow-up (data not shown). 29 of 42 evaluable patients 
at 2 year follow-up (1 patient was pregnant and 1 patient left the study) had signs of disease 
activity and were classified as EDA, whereas 13 had not and were classified as NEDA.  
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Figure 2. Neurodegenerative and neuroinflammatory markers in CSF at baseline in healthy 
controls and in CIS and MS patients subgrouped by disease activity during follow-up. Lines 
show median and interquartile range.  
*: P-value from Mann-Whitney U test for independent samples ≤ 0.01. 
**: P-value from Mann-Whitney U test for independent samples <0.001. 
ns: P-value from Mann-Whitney U test for independent samples >0.01.  
HC: Healthy controls 
NEDA: Patients with no evidence of disease activity during two years of follow-up (no 
relapses, no brain MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions) and no 
disability worsening) 
EDA: Patients with evidence of disease activity during two years of follow-up (relapses, brain 
MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions) or disability worsening) 
 
From an ROC curve (Figure 3) sensitivity and specificity for NFL levels at baseline in 
relation to disease activity at two year follow-up were calculated. With a cut off value of ≥450 
pg/ml for NFL, 97% of patients that showed disease activity in this cohort were identified, but 
the specificity was only 62%, while a cut-off value of ≥749 pg/ml gave a sensitivity of 72% 
and a specificity of 77%.  
 
 
 
Figure 3. Reciever operating characteristics (ROC) curve for NFL in CSF at baseline and 
evidence of disease activity in patients during two years of follow-up. Area under curve 
(AUC), representing the proportion of patients correctly classified as with or without disease 
activity, is 0.83, p=0.001. 
The predictive value of each one of the neurodegenerative and neuroinflammatory markers in 
CSF at baseline with regard to disease activity during follow-up was evaluated with logistic 
regression, as presented in supplementary Table S5. We found that NFL performed best at 
predicting disease activity status at two years, classifying 93% of EDA patients and 62% of 
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NEDA patients correctly. The overall correctly classified proportion of patients was 83% 
(Table 6). We then combined NFL with the other markers one by one. The only combinations 
that yielded a slightly higher overall percentage of correctly classified patients were 
NFL+OPN and NFL+CCL22. Combining NFL with both CCL22 and OPN correctly 
classified 93 % of patients with disease activity and 85 % of patients without disease activity, 
with an overall proportion of correctly classified patients of 91 % (Table 6). Of note is that 
baseline number of T2 hyperintense lesions in the brain was inferior to NFL at predicting 
disease activity and that combining NFL with number of T2 hyperintense lesions did not 
improve the model compared to NFL alone. NFL at baseline did not correlate with total 
number of T2 lesions in the brain at baseline or to new lesions in brain MRI during two years 
of follow-up.  
 
Table 6. Results from logistic regression analysis showing the ability of markers at baseline 
to predict disease activity during two years of follow-up.  
 
 Correctly predicted EDA (% out of 29 patients) 
Correctly predicted NEDA 
(% out of 13 patients) 
Overall correctly classified  
(% out of 42 patients) 
NFL  93 62 83 
NFL + NFH 93 62 83 
NFL + GFAP 93 62 83 
NFL + MMP-9 90 62 81 
NFL + CHI3L1 93 62 83 
NFL + OPN 93 69 86 
NFL + CXCL1 83 77 81 
NFL + CXCL8 90 54 79 
NFL + CXCL10 83 69 79 
NFL + CXCL13 93 62 83 
NFL + CCL22 86 85 86 
NFL + CCL22 + OPN 93 85 91 
T2 100  8 71 
EDSS 100 0 69 
NFL + T2  90 62 81 
EDA: Patients with evidence of disease activity during two years of follow-up (relapses, brain MRI 
activity (new or enlarging T2 lesions or Gd-enhancing lesions) or disability worsening) 
NEDA: Patients with no evidence of disease activity during two years of follow-up (no relapses, no 
brain MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions) and no disability worsening) 
T2: Total number of T2 hyperintense lesions in brain MRI at baseline 
EDSS: Expanded disability status scale at baseline 
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Discussion 
 
In the present study, we examined a prospective longitudinally followed cohort of patients 
with CIS and newly diagnosed MS to evaluate a broad set of both established and non-
established markers of neurodegeneration and neuroinflammation as potential prognostic 
markers of disease activity. Importantly, we show that NFL in CSF, with high accuracy 
predicted whether patients would show signs of disease activity during two years of follow-
up. Combining NFL with CSF-levels of OPN and CCL22 increased the overall correctly 
classified patients from 83% to 93%. Considering the heterogeneity in MS, prediction of 
disease activity using fluid biomarkers whould be of great value in decision of treatment 
strategy. Currently, clinical and radiological parameters are used for such decisions, but it 
should be noted that in the present study, T2 lesions at baseline did not add to the prediction 
of NEDA status.   
 
CSF levels of NFL in CIS patients have been reported as an independent prognostic marker 
for conversion from CIS to MS22, to correlate with multiple sclerosis severity score during 
long term follow-up in MS5 and to decrease on treatment7. To our knowledge this is the first 
study to demonstrate that NFL at baseline is a strong predictor of disease activity in the 
comprehensive form of NEDA-3 status after two years of follow-up in CIS and newly 
diagnosed MS. Thus, based on our and previous data, NFL in CSF emerges as a useful 
prognostic biomarker of disease activity. It has been shown that exposure to room temperature 
or repetitive thawing does not influence measurement of NFL concentrations23, which is of 
great value for a potential biomarker. NFL in CSF at baseline did not correlate with patient 
age at baseline in our study and we believe that this is due to the relatively low age of most 
patients in the cohort, since otherwise age should be taken into account when evaluating NFL 
levels24. We also evaluated several other suggested CSF biomarkers related to the process of 
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CNS tissue damage (NFH, GFAP, CHI3L1 and MMP-9), but in our setting, NFL in CSF 
stood out as the most useful prognostic biomarker of NEDA, with the highest discriminative 
capability also in relation to markers of neuroinflammation. 
 
After finding NFL at baseline as the sole marker with the highest potential to distinguish 
patients with disease activity after two years, we tested if combinations with markers of CSF 
inflammation could add to the discriminative power. OPN and CCL22 then emerged as useful 
since they, both alone and in combination, increased the proportion correctly predicted 
patients according to NEDA status at follow-up. In previous studies of OPN in MS, it was 
associated with ongoing disease activity15, but could also predict time to conversion from 
optic neuritis to MS, although it was outperformed by CHI3L1 in that setting25. In our study, 
OPN levels in CSF did not differ between patients and controls at baseline, and it was not 
increased at time of relapse. Still, it added to the prediction of disease activity after two years. 
OPN is a pleiotropic protein involved in several processes and it is not known by which 
mechanism it may contribute as a predictive biomarker. Interestingly, OPN was recently 
shown to be part of a module of dysregulated genes in activation of T helper cells in MS, 
indicating the involvement of T helper cell-associated mechanisms in the ability of OPN to 
contribute as a prognostic biomarker in MS. Although chemokines have been increasingly 
recognized as potential biomarkers, there has been little attention to CCL22 in MS, probably 
because it is induced by IL4 and IL-13 and involved in the recruitment of Th2 cells and in 
Th2 immunity26 which has not been considered relevant in MS. However, when measured in 
CSF of MS patients, CCL22 levels were increased in comparison with controls27, 28 and 
furthermore, CCL22 levels decreased after natalizumab treatment27. The present study is the 
first to  demonstrate that higher levels at baseline are associated with disease activity during 
follow-up.  
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NFL, OPN and CCL22 levels did not differ between patients in relapse and patients not in 
relapse at the time of CSF collection in our study. As for NFL22, 29 and OPN15, 30, data on 
levels in relation to relapse status are inconsistent, possibly because of differences in sample 
size and selection. Our finding of similar levels of NFL, OPN and CCL22 irrespective of 
relapse implies positive qualities as clinical biomarkers.  
 
A strength of this study is that the control group consisted of sex- and age-matched healthy 
individuals, not patients with “other neurological diseases” or patients examined due to a 
suspicion of neurological disease but without clinical findings indicating any CNS disorder. 
Another strength of this study is that the patient group consisted of are well-characterized MS 
patients examined and thoroughly followed-up by the same neurologist in a standardized way. 
A limitation of this study is the low sample size when stratifying into subgroups. Still, data 
were clear and consistent and we used a stringent statistical approach to compensate for 
multiple testing. The present study was designed to detect short-term effects, i.e. disease 
activity after two years, and future studies will address biomarkers in relation to long-term 
outcome including development of atrophy. Some of the analytes were not detected in CSF, 
which precluded evaluation as biomarker. Of note, none of the inflammatory markers in 
plasma were increased in patients versus controls and could not predict disease activity after 
two years, showing that CSF sampling is necessary to mirror the CNS inflammation. 
Regarding neuronal markers, it will be interesting to see whether super-sensitive assays of 
serum levels31 can add as biomarkers in MS.  
 
In conclusion, we show that NFL in CSF at diagnostic lumbar puncture in CIS and MS is able 
to predict disease activity as measured by NEDA status after two years. In combination with 
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previous studies, there is evidence to include NFL in CSF as a biomarker in clinical routine. 
We also show that combining NFL in CSF with markers of neuroinflammation seem to 
increase prognostic ability, which should be confirmed in larger studies. The use of 
biomarkers will be crucial in clinical practice as we want to individualize treatment early in 
the disease course.  
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Supplemental materials 
 
Patients stratified by diagnosis  
 
CSF levels of NFL, NFH, GFAP, MMP-9, CHI3L1, OPN, CXCL1, CXCL8, CXCL10, 
CCL13 and CCL22 in patients at baseline did not differ with regard to diagnosis CIS (n = 19), 
RRMS (n = 22) or PPMS (n = 3). Compared to HC (n = 23), CSF levels of NFL, MMP-9, 
CXCL8 and CXCL13 were higher in all patient subgroups, NFH, CXCL10 and CCL22 were 
higher in the CIS group and the RRMS group, CHI3L1 and CXCL1 were higher in the RRMS 
group and GFAP and OPN did not differ from HC in any patient group. Detailed data are 
presented in supplemental Table S1. Plasma levels of CXCL1, CXCL8, CXCL10, CXCL13, 
CCL20 and CCL22 at baseline did not differ between patient groups or between patient 
groups and HC (data not shown). 
 
Patients stratified by relapse status 
 
CSF levels of NFH were higher in patients with relapse at the time of baseline CSF collection, 
whereas the other markers in CSF did not differ between patients with regard to relapse status. 
CSF levels of NFL, MMP-9, CXCL8, CLCL10, CXCL13 and CCL22 at baseline were 
significantly higher in patients than in HC, regardless of relapse status. Levels of NFH and 
CXCL1 in CSF at baseline were higher in patients in relapse than in HC, but not in relapse-
free patients. Levels of CHI3L1 were higher in relapse-free patients than in HC (p 0.01) and 
showed a tendency to be higher in patients in relapse than in HC (p 0.03). Levels of GFAP 
and OPN in patients did not differ from HC, regardless of relapse status. CSF data for 
patients, subgrouped by relapse status, with time from onset of relapse within two months, 
and healthy controls are presented in supplemental Table S2.  
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Table S1. Neurodegenerative and neuroinflammatory markers in CSF in healthy controls and in patients at 
baseline, subgrouped by diagnosis. 
 
 CIS n=19 
RRMS 
n=22 
PPMS 
n=3 
HC 
n=23 
p MW 
(HC-CIS, HC-RRMS, HC-PPMS) 
NFL  724 
(207-2332) 
998 
(650-1447) 
743 
(616-1121) 
222  
(154-291) 
≤0.01, <0.001, ≤0.01 
NFH 48 
(16-73) 
33 
(16-56) 
65 
(33-71) 
16  
(16-16) 
≤0.01, ≤0.01, 0.03 
GFAP  453 
(324-642) 
489 
(374-627) 
749 
(453-820) 
442  
(344-500) 
0.71, 0.18, 0.06 
CHI3L1 85222  
(75436-
114464) 
117224  
(81168-
193442) 
149885  
(144979-
194116) 
73549  
(61412-
101061) 
0.21, ≤0.01, 0.02 
MMP-9  143 
(61-376) 
404 
(110-717) 
255 
(196-534) 
61  
(61-61) 
<0.001, <0.001, <0.001 
OPN 68  
(36-127) 
98  
(72-127) 
77  
(74-121) 
67  
(44-99) 
0.76, 0.04, 0.44 
CXCL1  8 
(8-18) 
21 
(8-25) 
8 
(8-27) 
8  
(8-8) 
0.11, <0.001, 0.65 
CXCL8  24 
(22-27) 
27 
(23-31) 
29 
(22-30) 
17  
(14-21) 
≤0.01, <0.001, ≤0.01 
CXCL10  885 
(750-1336) 
1533 
(886-2207) 
980 
(537-1606) 
540  
(450-818) 
≤0.01, <0.001, 0.16 
CXCL13  2 
(2-12) 
11 
(2-35) 
9 
(3-71) 
UD ≤0.01, <0.001, <0.001 
CCL22  17 
(8-27) 
44 
(14-71) 
34 
(8-52) 
8  
(8-8) 
<0.001, <0.001, 0.78 
Concentrations are given in pg/ml and presented as median and within brackets interquartile range, except for 
PPMS where minimum value and maximum values are given within brackets.  
UD = Under detection limit. 
p MW: P-values from Mann-Whitney U test for independent samples, comparing healthy controls to patients 
with CIS, RRMS and PPMS, respectively. Please note that to compare data from patients with different 
diagnoses and healthy controls, the Kruskal–Wallis test was first performed. When significant differences were 
found (p-values <0.05 in the Kruskal–Wallis test), the Mann–Whitney U-test was used as a post-hoc test to 
compare groups. P-values <0.01 in the Mann–Whitney U-test were considered to be significant. 
Please also note that p-values from Kruskal-Wallis test for independent samples comparing patients with 
diagnosis CIS, RRMS and PPMS were all >0.05 and therefore no Mann–Whitney U-test was used to compare 
these groups. 
HC-CIS = Healthy controls compared to patients with diagnosis clinically isolated syndrome 
HC-RRMS = Healthy controls compared to patients with diagnosis relapsing remitting multiple sclerosis 
HC-PPMS = Healthy controls compared to patients with diagnosis primary progressive multiple sclerosis 
 
 
Table S2. Neurodegenerative and neuroinflammatory markers in CSF in healthy controls and in patients, 
subgrouped by relapse status at time of baseline CSF collection.  
 
 
Relapse  
within two months 
n=23 
Relapse free 
n=21 
p MWa 
 
Healthy controls  
n=23 
p MWb 
r-HC, rf-HC 
 
NFL  1049 
(724-2332) 
697 
(258-1181) 
0.13 222  
(154-291) 
<0.001, <0.001 
 
NFH 58 
(32-105) 
16 
(16-51) 
≤0.01 16  
(16-16) 
<0.001, 0.09 
 
GFAP  499 
(381-642) 
453 
(334-698) 
0.85 442  
(344-500) 
0.17, 0.42 
 
CHI3L1 97919  103407  0.86 73549  0.03, ≤0.01 
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(75647-185171) (76192-180416) (61412-101061) 
MMP-9  376 
(61-612) 
219 
(61-622) 
0.77 61  
(61-61) 
<0.001, <0.001 
 
OPN 83  
(58-132) 
92  
(44-110) 
0.59 67  
(44-99) 
0.20, 0.46 
CXCL1  18 
(8-26) 
8 
(8-22) 
0.22 8  
(8-8) 
0.001, 0.04 
 
CXCL8  26 
(24-30) 
24 
(21-29) 
0.13 17  
(14-21) 
<0.001, <0.001 
 
CXCL10  1336 
(797-2280) 
980 
(790-1829) 
0.25 540  
(450-818) 
<0.001, <0.001 
 
CXCL13  7 
(2-48) 
4 
(2-16) 
0.71 UD <0.001, <0.001 
 
CCL22  21 
(8-61) 
21 
(8-50) 
0.42 8  
(8-8) 
<0.001, <0.001 
Concentrations are given in pg/ml and presented as median and within brackets interquartile range.  
UD = Under detection limit. 
p MWa: P-values from Mann-Whitney U test for independent samples, comparing patients in relapse and 
relapse free patients. 
p MWb: P-values from Mann-Whitney U test for independent samples, comparing healthy controls to 
patients in relapse and relapse free patients, respectively. 
r-HC = Patients in relapse compared to healthy controls 
rf-HC= Relapse free patients compared to healthy controls 
 
 
Table S3. Map of correlation analyses between neurodegenerative and neuroinflammatory markers in CSF at 
baseline.  
 
 NFL NFH GFAP CHI3L1 MMP-9  OPN CXCL1 CXCL8  CXCL10  CXCL13 CCL22 
NFL 1.00 0.57** 0.44* 0.60** 0.49* 0.43* 0.40* 0.47* 0.58** 0.54** 0.50* 
NFH  1.00 0.51** 0.34 0.18 0.35 0.08 0.28 0.32 0.36 0.11 
GFAP    1.00 0.56** 0.18 0.41* 0.15 0.25 0.22 0.34 0.12 
CHI3L1    1.00 0.44* 0.58** 0.50* 0.51** 0.57** 0.47* 0.43* 
MMP-9     1.00 0.40* 0.48* 0.50** 0.75** 0.82** 0.74** 
OPN      1.00 0.40* 0.38 0.48* 0.44* 0.31 
CXCL1       1.00 0.64** 0.62** 0.34 0.51** 
CXCL8        1.00 0.67** 0.33 0.40* 
CXCL10         1.00 0.62** 0.68** 
CXCL13          1.00 0.74** 
CCL22           1.00 
Magnitude of correlation coefficients (r) are shown, p-values according to bivariate non-parametric correlation analyses 
(Spearman). 
* p < 0.01 
** p < 0.001 
 
 
Table S4. Neurodegenerative and neuroinflammatory markers in CSF in healthy controls and at baseline in 
patients with NEDA/EDA for two years of follow-up.  
 
 NEDA  n=13 
EDA  
n=29 
pa 
 
HC 
n=23 
pb 
 
NFL  283  
(190-749) 
1081  
(726-2374) 
<0.001 222  
(154-291) 
0.11, <0.001 
NFH 16  53  ≤0.01 16  0.65, <0.001 
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(16-47) (32-86) (16-16) 
GFAP 352  
(322-528) 
499  
(395-650) 
0.03 442  
(344-500) 
0.52, 0.05 
CHI3L1 85222  
(68416-129721) 
125532  
(83201-203501) 
0.06 73549  
(61412-101061) 
0.33, 0.001 
MMP-9 196  
(61-242) 
376  
(130-712) 
0.05 61  
(61-61) 
≤0.01, <0.001 
OPN 68  
(34-92) 
104  
(73-144) 
≤0.01 67  
(44-99) 
0.58, 0.03 
CXCL1  8 
(8-19) 
19 
(8-26) 
≤0.01 8 
(8-8) 
0.49, <0.001 
CXCL8 22 
(17-27) 
26 
(24-30) 
0.02 17  
(14-21) 
0.04, <0.001 
CXCL10  797 
(495-1053) 
1606 
(939-2394) 
<0.001 540  
(450-818) 
0.15, <0.001 
CXCL13 2 
(2-5) 
12 
(3-43) 
≤0.01 ND 0.13, <0.001 
CCL22 8 
(8-18) 
40 
(14-66) 
≤0.01 8  
(8-8) 
0.04, <0.001 
Concentrations are given in pg/ml and presented as median and within brackets interquartile range. 
NEDA: No evidence of disease activity, defined as not having had any new relapse, not having progressed on 
EDSS and not having had any new T2 lesions or gadolinium enhancing T1 lesions for two years.  
EDA: Patients that do not fulfil criteria for NEDA as specified above. 
pa: P-values from Mann-Whitney U test for independent samples, comparing NEDA and EDA patients. 
pb: P-values from Mann-Whitney U test for independent samples, comparing first NEDA patients and healthy 
controls and then EDA patients and healthy controls. 
 
Table S5. Results from logistic regression analysis showing the ability of markers in CSF at 
baseline to predict disease activity during two years of follow-up.  
 
 
Correctly predicted 
EDA (% out of 29 
patients) 
Correctly predicted 
NEDA (% out of 13 
patients) 
Overall correctly 
classified  
(% out of 42 patients) 
NFL  93 62 83  
NFH 79 69 76  
GFAP 100 0 69  
CHI3L1 97 8 69  
MMP-9 100 0  69  
OPN 86 31 69  
CXCL1 69 69 69  
CXCL8 97 23 74  
CXCL10 86 54 76  
CXCL13 100 0 69  
CCL22 76 54 69  
EDA: Patients with evidence of disease activity during two years of follow-up (relapses, 
brain MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions) or disability 
worsening) 
NEDA: Patients with no evidence of disease activity during two years of follow-up (no 
relapses, no brain MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions) and 
no disability worsening) 
T2: Total number of T2 hyperintense lesions in brain MRI at baseline 
EDSS: Expanded disability status scale at baseline 
 
